Patents Assigned to Zeneca
  • Patent number: 6455520
    Abstract: The invention concerns amide derivatives of formula (I) wherein R3 is (1-6C)alkyl or halogeno; m is 0-3, p is 0-2 and q is 0-4; each of R1 and R2 is a group such as hydroxy, halogeno, trifluoromethyl and cyano; R4 is a basic group such as amino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, di-[(1-6C)alkyl]amino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(2-6C)alkoxy, heteroaryl, heteroaryloxy, heteroaryl-(1-6C)alkoxy, heterocyclyl, heterocyclyloxy and heterocyclyl-(1-6C)alkoxy; and Q2 is a group such as heteroaryl, heteroaryloxy or heteroaryl-(1-6C)alkoxy which is optionally substituted; or pharmaceutically-acceptable salts or in-vivo-cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.
    Type: Grant
    Filed: March 23, 2001
    Date of Patent: September 24, 2002
    Assignee: Astra Zeneca AB
    Inventors: Dearg S Brown, George R Brown
  • Patent number: 6455688
    Abstract: DNA sequence of an acetyl Coenzyme A carboxylase from plants are inserted into the genome of plants in sense or antisense orientation in order to inhibit expression of the gene product of the endogenous ACCase gene, resulting in reduced conversion of the enzyme's substrate, acetyl Coenzyme A, to fatty acid synthesis, leaving the substrate available for diversion into other biosynthesis pathways. One such diversion may be accomplished by providing the plant genome with genes specifying the synthesis of polyhydroxyalkanoate polymers.
    Type: Grant
    Filed: October 21, 1996
    Date of Patent: September 24, 2002
    Assignee: Zeneca Limited
    Inventors: Antoni Ryzsard Slabas, Kieran Michael Elborough, Simon William Jonathan Bright, Phillip Anthony Fentem
  • Patent number: 6448280
    Abstract: This invention relates to the use of angiotensin II antagonists in treating or preventing the development of disease conditions associated with impaired neuronal conduction velocity, such as diabetic neuropathy, as well as their use in the manufacture of a medicament for use in such treatment. The invention also concerns pharmaceutical compositions containing an angiotensin II antagonist together with one or more other agents known to be of value in treating or preventing the development of disease conditions associated with impaired neuronal conduction velocity.
    Type: Grant
    Filed: January 5, 1995
    Date of Patent: September 10, 2002
    Assignee: Zeneca Limited
    Inventors: Frank Carey, Alexander Anthony Oldham, Norman Eugene Cameron, Mary Anne Cotter
  • Patent number: 6444809
    Abstract: Compounds of formula I wherein G, J, L, M, m and D have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.
    Type: Grant
    Filed: September 22, 2000
    Date of Patent: September 3, 2002
    Assignee: Zeneca Limited
    Inventor: Scott Carson Miller
  • Publication number: 20020119968
    Abstract: The invention concerns compounds of formula (I) 1
    Type: Application
    Filed: March 8, 2001
    Publication date: August 29, 2002
    Applicant: ZENECA LIMITED
    Inventors: Alan Wellington Faull, Andrew Stocker, Colette Marie Mayo, John Preston
  • Patent number: 6441004
    Abstract: The invention concerns the use of a compound of the formula (I) in which Z, X, T, A, R1, R2, p and q have any of the meanings defined herein, and their pharmaceutically acceptable salts or in vivo hydrolysable esters, in the treatment of a disease or condition mediated by monocyte chemoattractant protein-1 (MCP-1). Certain of the components of formula (I) are novel and are provided, together with pharmaceutical compositions thereof, as further features of the invention.
    Type: Grant
    Filed: February 3, 2000
    Date of Patent: August 27, 2002
    Assignee: Zeneca Limited
    Inventors: Alan Wellington Faull, Andrew John Barker, Jason Grant Kettle
  • Patent number: 6440972
    Abstract: This invention concerns heterocyclic derivatives of formula (I) which are useful in inhibiting oxido-squalene cyclase, processes for their preparation and pharmaceutical compositions containing them. The present invention is also concerned with heterocyclic derivatives capable of inhibiting cholesterol biosynthesis and hence the lowering cholesterol levels in blood plasma. The present invention also relates to methods of using such heterocyclic derivatives in diseases and medical conditions such as hypercholesterolemia and atherosclerosis.
    Type: Grant
    Filed: August 13, 1999
    Date of Patent: August 27, 2002
    Assignee: Zeneca Limited
    Inventor: George Robert Brown
  • Patent number: 6436691
    Abstract: Antibody Directed Enzyme Prodrug Therapy (ADEPT) systems for use in cancer based on mutated carboxypeptidase B (CPB) enzymes. Enzyme conjugates for ADEPT are substantially non-immunogenic in humans comprising a targeting moiety (for example an antibody) capable of binding with a tumor associated antigen, the targeting moiety being linked to a mutated form of a CPB enzyme capable of converting a prodrug into an antineoplastic drug wherein the prodrug is not significantly convertible into antineoplastic drug in humans by natural unmutated enzyme. A preferred enzyme mutant is human pancreatic CPB comprising a Lys or Arg residue at position 253. Suitable mustard prodrugs are disclosed in the specification.
    Type: Grant
    Filed: February 13, 1998
    Date of Patent: August 20, 2002
    Assignee: Zeneca Limited
    Inventors: Anthony Michael Slater, David Charles Blakey, David Huw Davies, John Frederick Hennam, Laurent Francois Andre Hennequin, Peter Robert Marsham, Robert Ian Dowell
  • Patent number: 6423731
    Abstract: A method for the prophylaxis or treatment of conditions for which 5-HT1-like agonists are indicated comprising the administration of therapeutically-effective amount of compounds of formula (I) wherein A, W, Z and n are as defined in the specification.
    Type: Grant
    Filed: January 12, 2001
    Date of Patent: July 23, 2002
    Assignee: Zeneca Limited
    Inventors: Robert John Blade, Yih Sang Pang, David Lawrence Selwood
  • Patent number: 6414145
    Abstract: The present invention relates to inhibitors of ras farnesylation of Formula (I), wherein T is of Formula (1) or (2) or (3); A is aryl or heteroaryl; B is aryl or heteroaryl; X and Y represent hydrogen, or both X and Y can represent a single bond (so as to form a double bond); R1 represents a group of Formula (II) or (III), the group of Formula (II) or Formula (III) (having L or D configuration at the chiral alpha carbon in the corresponding free amino acid); R2 represents hydrogen, aryl or heteroaryl; Z represents a direct bond, methylene, ethylene, vinylene, oxy, —CH2—O— or —O—CH2—; and R3—R4, p and r are as defined in the specification or a pharmaceutically-acceptable salt, prodrug or solvate thereof. Processes for their preparation, their use as therapeutic agents and pharmaceutical compositions containing them.
    Type: Grant
    Filed: July 28, 1999
    Date of Patent: July 2, 2002
    Assignees: Zeneca Limited, Zeneca Pharma S.A.
    Inventors: Francis Thomas Boyle, Gareth Morse Davies, James Michael Wardleworth, Jean-Claude Arnould
  • Patent number: 6413727
    Abstract: A human gene termed APC is disclosed. Methods and kits are provided for assessing mutations of the APC gene in human tissues and body samples. APC mutations are found in familial adenomatous polyposis patients as well as in sporadic colorectal cancer patients. APC is expressed in most normal tissues. These results suggest that APC is a tumor suppressor.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: July 2, 2002
    Assignees: The Johns Hopkins University, University of Utah, Japanese Foundation for Cancer Research Cancer Institute, Zeneca Limited
    Inventors: Hans Albertsen, Rakesh Anand, Mary Carlson, Joanna Groden, Philip John Hedge, Geoff Joslyn, Kenneth Kinzler, Alexander Fred Markham, Yusuke Nakamura, Andrew Thliveris, Bert Vogelstein, Raymond L. White
  • Patent number: 6414148
    Abstract: The invention relates to quinazoline derivatives of formula (1) wherein m is an integer from 1 to 2; R1 represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, or —NR5R6 (wherein R5 and R6, which may be the same or different, each represents hydrogen or C1-3alkyl); R2 represents hydrogen, hydroxy, halogeno, methoxy, amino or nitro; R3 represents hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro; X1 represents —O—, —CH2—, —S—, —SO—, —SO2—, —NR7CO—, —CONR8—, —SO2NR9—, —NR10SO2— or —NR11— (wherein R7, R8, R9, R10 and R11 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl); R4 represents an optionally substituted 5 or 6 membered saturated carbocyclic or heterocyclic group or a group which is alkenyl, alkynyl or optionally substituted alkyl, which alky
    Type: Grant
    Filed: March 25, 1999
    Date of Patent: July 2, 2002
    Assignees: Zeneca Limited, Zeneca Pharma S.A.
    Inventors: Andrew Peter Thomas, Craig Johnstone, Edward Clayton, Elaine Sophie Elizabeth Stokes, Jean-Jacques Marcel Lohmann, Laurent Francois Andre Hennequin
  • Patent number: 6410539
    Abstract: The present invention relates to a compound of Formula (1) wherein Ar1 represent (A) or (B) or (C); R1 is hydrogen, C1-4alkyl or C1-4alkanoyl; R12 and R13 are independently hydrogen or C1-4alkyl; Ar2 is phenyl or heteroaryl; p is 0 or 1; Ar3 is of formula (I) wherein W, X, Y and Z are independently CH or N, provided that at least two of W, X, Y and Z are CH and R2 and —(CH2)nR3 are attached to ring carbon atoms; R2 is a group of Formula (II) or R2 represents a lactone of Formula (III) the group of Formula (II) or (III) having L or D configuration at the chiral alpha carbon in the corresponding free amino acid; n is 0, 1 or 2; R3 is phenyl or heteroaryl; provided that: when n is 0, Ar3 is substituted by R2 in the 4-position and —(CH2)nR3 in the 3- or 5-position; and when n is 1 or 2, Ar3 is substituted by R2 in the 3- or 5-position and —(CH2)nR3 in the 4-position; and R5-R9, m and n are as defined in the specification; or a pharmaceutically-acceptable salt, prodrug or solvate thereof.
    Type: Grant
    Filed: March 24, 2000
    Date of Patent: June 25, 2002
    Assignees: Astrazenca UK Limited, Zeneca Pharma SA
    Inventor: Jean-Claude Arnould
  • Publication number: 20020077484
    Abstract: A process for making a 2-alkylbenzisothiazolinone which comprises reacting a bisamide of formula 1
    Type: Application
    Filed: January 23, 2002
    Publication date: June 20, 2002
    Applicant: Zeneca Limited
    Inventor: Mark Robert James
  • Patent number: 6399602
    Abstract: The invention concerns quinazoline derivatives of the formula I wherein X1 is a direct link or a group such as CO, C(R2)2 and CH(OR2); wherein Q1 is phenyl, naphthyl or a 5- or 6-membered heteroaryl moiety and Q1 optionally bears up to 3 substituents; wherein m is 1 or 2 and each R1 may be a group such as hydrogen, halogeno and trifluoromethyl; and wherein Q2 may be phenyl or a 9- or 10-membered bicyclic heterocyclic moiety and Q2 optionally bears up to 3 substituents; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and the use of their receptor tyrosine kinase inhibitory properties in the treatment of proliferative disease such as cancer.
    Type: Grant
    Filed: September 11, 1998
    Date of Patent: June 4, 2002
    Assignee: Zeneca Limited
    Inventors: Andrew John Barker, Craig Johnstone
  • Patent number: 6395963
    Abstract: Nematode-inducible promoter sequences are disclosed. These sequences can be used for expressing DNA sequences in plant cells. Chimeric DNA constructs comprising the nematode-inducible promoter sequences operably linked to DNA to be expressed in plant cells are also disclosed. Plants comprising the chimeric DNA are provided.
    Type: Grant
    Filed: May 17, 1999
    Date of Patent: May 28, 2002
    Assignee: Zeneca Limited
    Inventors: Stephan Andreas Ohl, Peter Christiaan Sijmons, Frédérique Marianne Klein-Van der Lee, Oscar Goddijn, Joke Klap
  • Patent number: 6391880
    Abstract: This invention concerns heterocyclic derivatives of formula (I) which are useful in inhibiting oxido-squalene cyclase, processes for their preparation and pharmaceutical compositions containing them. The present invention is also concerned with heterocyclic derivatives capable of inhibiting cholesterol biosynthesis and hence in lowering cholesterol levels in blood plasma. The present invention also relates to methods of using such heterocyclic derivatives in diseases and medical conditions such as hypercholesterolemia and atherosclerosis.
    Type: Grant
    Filed: August 13, 1999
    Date of Patent: May 21, 2002
    Assignee: Zeneca Limited
    Inventors: Alan John Foubister, George Robert Brown, Nicholas John Newcombe
  • Patent number: 6383782
    Abstract: Novel Analogues of Monocyte Chemoattractant Protein-1 (MCP-1) have substitution of an alanine, glycine or threonine for the natural valine in position 9 of MCP-1 (9-76).
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: May 7, 2002
    Assignee: Zeneca Limited
    Inventors: Derek Graham Barratt, Maurice Ronald Charles Needham
  • Patent number: 6379945
    Abstract: The invention relates to an insect steroid receptor protein which is capable of acting as a gene switch which is responsive to a chemical inducer enabling external control of the gene.
    Type: Grant
    Filed: May 24, 1996
    Date of Patent: April 30, 2002
    Assignee: Zeneca Limited
    Inventors: Ian Jepson, Alberto Martinez, Andrew James Greenland
  • Patent number: 6380463
    Abstract: The invention relates to DNA constructs which are capable of conferring on a plant inducible resistance to a herbicide. The inducible effect may be achieved by using a gene switch such as the alcA/alcR switch derived from A. nidulans. The invention relates in particular to inducible resistance to the herbicide N-phosphonomethyl glycine (glyphosate) and its salts.
    Type: Grant
    Filed: January 29, 1998
    Date of Patent: April 30, 2002
    Assignee: Zeneca Limited
    Inventor: Ian Jepson